F8 and hemophilia A: An early cost-effectiveness analysis compared valoctocogene roxaparvovec with standard half-life FVIII or emicizumab in patients with severe hemophilia A without FVIII antibodies using a Dutch societal perspective with a 10-year time horizon [108].